Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Revision in appointed date of merger

 With reference to the earlier letter dated March 1, 2016, wherein the Company had informed that the board has considered the merger of Lyka Healthcare Limited and Lyka Exports Limited, subsidiaries with Lyka Labs Limited with effect from April 01, 2015.Lyka Labs Ltd has informed BSE that as advised by the Company's consultants and merchant bankers, the Board of Directors at their meeting held on June 04, 2016 has reconsidered the date of merger w.e.f. April 01, 2016.
04-06-2016
Bigul

Standalone & Consolidated Financial Results, Form B, Auditors Report for March 31, 2016

 Lyka Labs Ltd has informed BSE about : 1. Standalone Financial Results for the period ended March 31, 20162. Consolidated Financial Results for the period ended March 31, 20163. Standalone Form B for the period ended March 31, 20164. Standalone Auditors Report for the period ended March 31, 20165. Consolidated Auditors Report for the period ended March 31, 2016
28-05-2016
Bigul

Annual report for Lyka Labs Ltd. for FY-2016
28-05-2016
Bigul

Board Meeting Intimation for Results

 Lyka Labs Ltd has informed BSE that the meeting of the Board of Directors of the Company is convened on May 27, 2016, for consideration and adoption of Audited Standalone and Consolidated Financial Results for the Third Quarter and Financial Year of nine months ended March 31, 2016 and Audited Annual Accounts for the year ended March 31, 2016.
20-05-2016
Bigul

Shareholding for the Period Ended March 31, 2016

 Lyka Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here
15-04-2016
Bigul

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016

 Lyka Labs Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
15-04-2016
Bigul

Lyka Labs launches two marketing units

 Lyka Labs has informed the exchanges that Lyka Healthcare Ltd, a wholly owned subsidiary of the company, has launched two domestic marketing divisions - Enspan and Cerabelle. Enspan would be marketing...
11-04-2016
Bigul

Launch of New Marketing Divisions

 Lyka Labs Ltd has informed BSE that Lyka Healthcare Limited, a wholly owned subsidiary of Lyka Labs Limited, has launched two domestic marketing divisions in the name of ENSPAN and CERABELLE. Enspan would be marketing Critical and Anesthesia range of Products and Cerabelle would be marketing Dermatology and Cosmetology range of Products.The above products would also be offered internationally in the 46 countries in which Lyka has its presence.
11-04-2016
Bigul

Outcome of Board Meeting

 Lyka Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 11, 2016, have considered merger of Lyka Healthcare Limited, a wholly owned subsidiary and Lyka Exports Limited, a subsidiary with Lyka Labs Limited with effect from April 01, 2015.
11-03-2016
Bigul

Board Meeting on Mar 11, 2016

 Lyka Labs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on March 11, 2016, to consider / discuss / approve merger of Lyka Healthcare Ltd, a wholly owned subsidiary and Lyka Exports Ltd, a subsidiary with Lyka Labs Ltd.
05-03-2016
Next Page
Close

Let's Open Free Demat Account